Alx Oncology Holdings (ALXO) Retained Earnings (2019 - 2026)
Alx Oncology Holdings recorded quarterly Retained Earnings of -$740.7 million in Q1 2026, down 2.48% quarter-over-quarter from -$722.8 million in Q4 2025, and down 627849.15% year-over-year from N/an in Q1 2025.
Alx Oncology Holdings' Retained Earnings history runs 8 years deep, the most recent figure standing at -$740.7 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 627849.15% year-over-year to -$740.7 million; the TTM figure through Mar 2026 stood at -$740.7 million (down 627849.15% YoY), while the FY2025 annual figure was -$722.8 million, down 16.37% from the prior year.
- Retained Earnings came in at -$740.7 million for Q1 2026 at Alx Oncology Holdings, down from -$722.8 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $563000.0 in Q3 2024 to a low of -$740.7 million in Q1 2026.
- A 5-year average of -$242.0 million and a median of -$845000.0 in 2022 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings jumped 349.12% in 2024 and sank 928427.4% in 2025, its largest moves.
- Alx Oncology Holdings' Retained Earnings stood at -$845000.0 in 2022, then soared by 130.3% to $256000.0 in 2023, then sank by 242725.78% to -$621.1 million in 2024, then retreated by 16.37% to -$722.8 million in 2025, then dropped by 2.48% to -$740.7 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$740.7 million, -$722.8 million, and -$700.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | -740.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -740.74 Mn |
| Dec 31, 2025 | -722.82 Mn |
| Sep 30, 2025 | -699.97 Mn |
| Jun 30, 2025 | -677.83 Mn |
| Mar 31, 2025 | 118,000.00 |
| Dec 31, 2024 | -621.12 Mn |
| Sep 30, 2024 | 563,000.00 |
| Jun 30, 2024 | -73,000.00 |
| Mar 31, 2024 | 28,000.00 |
| Dec 31, 2023 | 256,000.00 |
| Sep 30, 2023 | -226,000.00 |
| Jun 30, 2023 | -389.81 Mn |
| Mar 31, 2023 | -88,000.00 |
| Dec 31, 2022 | -845,000.00 |
| Sep 30, 2022 | -1.50 Mn |
| Jun 30, 2022 | -259.44 Mn |
| Mar 31, 2022 | -606,000.00 |
| Dec 31, 2021 | -201.99 Mn |
| Sep 30, 2021 | -173.55 Mn |
| Jun 30, 2021 | -148.98 Mn |
| Mar 31, 2021 | -132.71 Mn |
| Dec 31, 2020 | -118.52 Mn |
| Sep 30, 2020 | -99.75 Mn |
| Jun 30, 2020 | -89.57 Mn |
| Dec 31, 2019 | -72.78 Mn |